Gc Biopharma Corp
Clinical trials sponsored by Gc Biopharma Corp, explained in plain language.
A biopharmaceutical company developing plasma-derived and recombinant therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Hunterase extended trial shows promise for managing hunter syndrome
Disease control CompletedThis study looked at the long-term safety and effectiveness of Hunterase (idursulfase beta) in 30 people with Hunter syndrome over about one year. Participants had either completed a previous phase 3 study or had used Hunterase for at least six months. The goal was to monitor sid…
Phase: PHASE3 • Sponsor: GC Biopharma Corp • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hemophilia shot shows early promise in small safety trial
Disease control CompletedThis early-phase study tested a new drug called MG1113, given as a shot under the skin, in 15 adults with severe hemophilia A or B. The main goal was to check safety and how the drug moves through the body. Participants received multiple doses to see if the drug is well-tolerated…
Phase: PHASE1 • Sponsor: GC Biopharma Corp • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC